JP2021510833A5 - - Google Patents
Info
- Publication number
- JP2021510833A5 JP2021510833A5 JP2020558659A JP2020558659A JP2021510833A5 JP 2021510833 A5 JP2021510833 A5 JP 2021510833A5 JP 2020558659 A JP2020558659 A JP 2020558659A JP 2020558659 A JP2020558659 A JP 2020558659A JP 2021510833 A5 JP2021510833 A5 JP 2021510833A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- treatment
- k263ac
- k263me
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900108 | 2018-01-15 | ||
| AU2018900108A AU2018900108A0 (en) | 2018-01-15 | Proteinaceous molecules and uses therefor | |
| AU2018900392A AU2018900392A0 (en) | 2018-02-08 | “agents and methods for predicting response to therapy” | |
| AU2018900392 | 2018-02-08 | ||
| PCT/AU2019/050025 WO2019136532A1 (en) | 2018-01-15 | 2019-01-15 | Agents and methods for predicting response to therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510833A JP2021510833A (ja) | 2021-04-30 |
| JP2021510833A5 true JP2021510833A5 (enExample) | 2022-02-07 |
| JP7236164B2 JP7236164B2 (ja) | 2023-03-09 |
Family
ID=67218185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558659A Active JP7236164B2 (ja) | 2018-01-15 | 2019-01-15 | 治療法に対する応答を予測する薬剤及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12174193B2 (enExample) |
| EP (1) | EP3740756A4 (enExample) |
| JP (1) | JP7236164B2 (enExample) |
| CN (1) | CN111936857B (enExample) |
| AU (1) | AU2019207535B2 (enExample) |
| CA (1) | CA3087779A1 (enExample) |
| SG (1) | SG11202006441SA (enExample) |
| WO (1) | WO2019136532A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022162665A1 (en) * | 2021-01-28 | 2022-08-04 | Ariel Scientific Innovations Ltd. | Setdb1-microtubule interaction and use thereof |
| CN113109565B (zh) * | 2021-04-12 | 2024-02-02 | 中国人民解放军空军军医大学 | 一种评估患者对pd-1单抗产品敏感性的检测盒及其应用 |
| CN117999357A (zh) | 2021-06-14 | 2024-05-07 | 波士顿大学董事会 | 用于检测细胞应激的方法 |
| CN115248313A (zh) * | 2022-08-03 | 2022-10-28 | 中山市人民医院 | 肠癌外周血免疫细胞m5C标志物的应用 |
| CN116381235A (zh) * | 2022-11-28 | 2023-07-04 | 中国人民解放军海军军医大学第三附属医院 | 一种生物标志物sod3及其在肝癌治疗中的应用 |
| WO2025234833A1 (en) * | 2024-05-10 | 2025-11-13 | Lunit Inc. | Method and device for predicting cancer treatment response to immune checkpoint inhibitor |
| CN118522475B (zh) * | 2024-07-22 | 2024-10-29 | 杭州茵菲多组学生物科技有限公司 | 基于组织原位质谱成像技术的非小细胞肺癌免疫检查点抑制剂疗法疗效评估方法及系统 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| WO2001031580A2 (en) | 1999-10-27 | 2001-05-03 | Biowulf Technologies, Llc | Methods and devices for identifying patterns in biological systems |
| US6925389B2 (en) | 2000-07-18 | 2005-08-02 | Correlogic Systems, Inc., | Process for discriminating between biological states based on hidden patterns from biological data |
| AU2002245043B2 (en) | 2000-11-16 | 2006-10-26 | Bio-Rad Laboratories, Inc. | Method for analyzing mass spectra |
| US7113896B2 (en) | 2001-05-11 | 2006-09-26 | Zhen Zhang | System and methods for processing biological expression data |
| US20020193950A1 (en) | 2002-02-25 | 2002-12-19 | Gavin Edward J. | Method for analyzing mass spectra |
| US9689876B2 (en) * | 2012-05-02 | 2017-06-27 | New York University | Methods related to cancer treatment |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CA2901513C (en) | 2013-03-12 | 2020-12-29 | Ventana Medical Systems, Inc. | Proximity assay for in situ detection of targets |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| CN111729090A (zh) * | 2013-12-20 | 2020-10-02 | 通用医疗公司 | 与循环肿瘤细胞相关的方法和测定法 |
| US9856315B2 (en) | 2014-10-15 | 2018-01-02 | Cell Signaling Technology, Inc. | Methylation and acetylation sites |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| WO2016160792A1 (en) * | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| JP2021510538A (ja) * | 2018-01-15 | 2021-04-30 | エピアクシス セラピューティクス プロプライエタリー リミテッド | タンパク質性分子およびその使用 |
-
2019
- 2019-01-15 AU AU2019207535A patent/AU2019207535B2/en active Active
- 2019-01-15 US US16/962,181 patent/US12174193B2/en active Active
- 2019-01-15 CA CA3087779A patent/CA3087779A1/en not_active Abandoned
- 2019-01-15 JP JP2020558659A patent/JP7236164B2/ja active Active
- 2019-01-15 EP EP19738581.8A patent/EP3740756A4/en active Pending
- 2019-01-15 SG SG11202006441SA patent/SG11202006441SA/en unknown
- 2019-01-15 CN CN201980019179.6A patent/CN111936857B/zh active Active
- 2019-01-15 WO PCT/AU2019/050025 patent/WO2019136532A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510833A5 (enExample) | ||
| Ren et al. | TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity | |
| Yan et al. | Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation | |
| Timofeeva et al. | Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls | |
| Wang et al. | Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma | |
| Zhou et al. | Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment | |
| Samuel et al. | Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers | |
| McAndrew et al. | Effects of systemic inflammation on relapse in early breast cancer | |
| Huang et al. | SOX2 promotes vasculogenic mimicry by accelerating glycolysis via the lncRNA AC005392. 2-GLUT1 axis in colorectal cancer | |
| Meng et al. | Roles of lncRNA LVBU in regulating urea cycle/polyamine synthesis axis to promote colorectal carcinoma progression | |
| Cheng et al. | Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma | |
| Fuentes-Rodriguez et al. | Recent advances in molecular and genetic research on uveal melanoma | |
| Zhang et al. | Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma | |
| Jang et al. | Proteomics of primary uveal melanoma: insights into metastasis and protein biomarkers | |
| Zhang et al. | The prognostic role of FZD6 in esophageal squamous cell carcinoma patients | |
| Liu et al. | The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer | |
| Chen et al. | SAMHD1, positively regulated by KLF4, suppresses the proliferation of gastric cancer cells through MAPK p38 signaling pathway | |
| Li et al. | TRIM31 triggers colorectal carcinogenesis and progression by maintaining YBX1 protein stability through ubiquitination modification | |
| Abou-Fadel et al. | Key members of the cmpn as biomarkers distinguish histological and immune subtypes of hepatic cancers | |
| Zuo et al. | Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma | |
| Wang et al. | Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma | |
| Zhang et al. | The predictive value of monocarboxylate transporter 4 (MCT4) on lung adenocarcinoma patients treated with PD-1 inhibitors | |
| Kikuta et al. | Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Cengiz et al. | Can serum pin1 level be regarded as an indicative marker of nonalcoholic steatohepatitis and fibrotic stages? |